Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Glycoprotein 41 (gp41) - Pipeline Review, H2 2016', provides in depth analysis on Glycoprotein 41 (gp41) targeted pipeline therapeutics. 

The report provides comprehensive information on the Glycoprotein 41 (gp41), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycoprotein 41 (gp41) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Glycoprotein 41 (gp41) Overview 8
Therapeutics Development 9
Glycoprotein 41 (gp41) - Products under Development by Stage of Development 9
Glycoprotein 41 (gp41) - Products under Development by Therapy Area 10
Glycoprotein 41 (gp41) - Products under Development by Indication 11
Glycoprotein 41 (gp41) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Glycoprotein 41 (gp41) - Products under Development by Companies 14
Glycoprotein 41 (gp41) - Products under Development by Universities/Institutes 16
Glycoprotein 41 (gp41) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development 24
Amunix Operating Inc. 24
BioClonetics Immunotherapeutics, Inc. 25
ConjuChem, LLC 26
Frontier Biotechnologies Co., Ltd 27
InnaVirVax SA 28
Longevity Biotech, Inc 29
Mymetics Corporation 30
Navigen Pharmaceuticals, Inc. 31
Osel, Inc. 32
Pharis Biotec GmbH 33
Glycoprotein 41 (gp41) - Drug Profiles 34
Biologic for Infectious Disease - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
CLONE-3 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CPT-31 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DAC-HIV - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
DS-007 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Enfuvirtide-XTEN - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
FB-006M - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
HIV-1 vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
LBT-5001 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
MYMV-101 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
MYMV-201 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Recombinant Peptides for HIV-1 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
STOP-3S - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Synthetic Peptide to Target gp41 for HIV Infection - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
VAC-02 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
VAC-3S - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
VIR-576 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Glycoprotein 41 (gp41) - Dormant Projects 59
Glycoprotein 41 (gp41) - Featured News & Press Releases 60
Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development 60
Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial 61
Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed 61
Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic 63
Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine 64
Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics 65
Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry" 65
Dec 01, 2013: InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection 66
Mar 05, 2013: InnaVirVax Presents Results From Phase I/IIa Clinical Study Of VAC-3S At CROI 2013 67
Feb 21, 2013: Mymetics Announces Publication Of Positive Phase I Study Results Of HIV-1 Vaccine In PLOS ONE 67
Nov 30, 2012: InnaVirVax's HIV Vaccine VAC-3S Achieves Primary End Point In Phase I/IIa Study 68
Jun 18, 2012: InnaVirVax Files New European Patent Application For VAC-3S Immunotherapy 69
Mar 05, 2012: InnaVirVax Initiates Phase I/IIa Clinical Trial Of VAC-3S For Treatment Of HIV Infections 69
Oct 13, 2011: InnaVirVax Obtains Authorization From French Drug Agency To Start Phase I/IIa Study Of VAC-3S 70
Jun 22, 2011: InnaVirVax Announces Positive Preclinical Results Of VAC-3S For Treatment Of HIV Infections 71

Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Amunix Operating Inc., H2 2016 24
Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016 25
Pipeline by ConjuChem, LLC, H2 2016 26
Pipeline by Frontier Biotechnologies Co., Ltd, H2 2016 27
Pipeline by InnaVirVax SA, H2 2016 28
Pipeline by Longevity Biotech, Inc, H2 2016 29
Pipeline by Mymetics Corporation, H2 2016 30
Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 31
Pipeline by Osel, Inc., H2 2016 32
Pipeline by Pharis Biotec GmbH, H2 2016 33
Dormant Projects, H2 2016 59